![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Artemis Therapeutics Inc (PK) | USOTC:ATMS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.498 | 0.181 | 0.50 | 0.00 | 01:00:00 |
UNITED STATES
|
OMB APPROVAL
|
SECURITIES AND EXCHANGE COMMISSION
|
OMB Number: . . . . . 3235-0058
|
Washington, D.C. 20549
|
Expires: April 30, 2025
|
|
Estimated average burden hours
|
FORM 12b-25
|
per response. . . . . . . . 2.50
|
|
|
NOTIFICATION OF LATE FILING
|
|
|
SEC FILE NUMBER
|
|
001-24431
|
|
|
|
CUSIP NUMBER
|
|
04302Q109
|
|
|
(Check one):
|
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
|
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
☒
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following
the prescribed due date; and
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
Shimon Citron
|
|
(972)
|
|
77-407-4700
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in
the subject report or portion thereof?
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
|
ARTEMIS THERAPEUTICS, INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date
|
May 15, 2023
|
|
By:
|
/s/ Shimon Citron
|
|
|
|
|
Shimon Citron
|
|
|
|
|
Chief Executive Officer and Director
|
1 Year Artemis Therapeutics (PK) Chart |
1 Month Artemis Therapeutics (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions